Medroxyprogesterone 17-acetate; Metigestrona; Provera; Depo-Provera; Farlutin; Methylacetoxyprogesterone; Medroxyacetate progesterone; Depcorlutin; Deporone; Supprestral; Lutoral; Promone-E; Medroxyprogesteroneacetate; 6-alpha-Methyl-17-alpha-acetoxyprogesterone; Gestapuran; Perlutex; Veramix; NSC-26386; 17alpha-Hydroxy-6alpha-methylprogesterone acetate; 6alpha-Methyl-17alpha-hydroxyprogesterone acetate; Lutopolar; Nadigest; Prodasone; Progestalfa; Progevera; Proverone; Repromix; Sirprogen; Nidaxin; Oragest; Depo-Promone; Depot medroxyprogesterone acetate; UNII-C2QI4IOI2G; DP150; 17-Acetoxy-6alpha-methylprogesterone; Aragest; Clinovir; Ralovera; 6alpha-Methyl-17-acetoxy progesterone; Hysron; Provera dosepak; Depo-clinovir; Depo-Ralovera; U 8839; C2QI4IOI2G; Depot-medroxyprogesterone acetate; Medroxyprogesterone-17-acetate; MLS000069442; ONCO-Provera; NSC-21171; Medrosterona; Cykrina; Depocon; Mepastat; SMR000059125; Sumiferm; Suprestral; Veraplex; Dugen; Depo-Progevera; DSSTox_CID_5527; Depo-Map; MPA-beta; DSSTox_RID_77819; MPA Hexal; MPA-Noury; DSSTox_GSID_25527; MAP (steroid); 17alpha-Acetoxy-6alpha-methylprogesterone; Depomedroxyprogesterone acetate; Medroxyprogesterone acetate, 97%; MPA GYM; Depo-Medroxyprogesterone acetate; Depo-subq provera; CCRIS 371; 17.alpha.-Acetoxy-6.alpha.-methylprogesterone; EINECS 200-757-9; 6alpha-Methyl-17-acetoxyprogesterone; NSC 21171; Depo-Provera Contraceptive; 17-Acetoxy-6-alpha-methylprogesterone; (6.alpha.-Pregn-4-ene-3, 17-(acetyloxy)-6-methyl-; 6-alpha-Methyl-17-acetoxy progesterone; BRN 2066112; Progestins; AI3-60127; 17-Acetoxy-6.alpha.-methylprogesterone; 6.alpha.-Methyl-17-acetoxyprogesterone; NCGC00094713-01; Progesterone, 17-hydroxy-6alpha-methyl-, acetate; Provera (TN); Depo-provera (TN); Medroxyprogesterone acetate [USP:JAN]; Medroxyprogesterone acetate [Progestins]; 6.alpha.-Methyl-17.alpha.-acetoxyprogesterone; PubChem13062; CPD000653524; Opera_ID_1110; Medroxiprogesterone Acetate; CHEMBL717; SCHEMBL4276; Medroxyprogesterone (acetate); 4-08-00-02212 (Beilstein Handbook Reference); MLS001148217; MLS002207115; Depo-subq provera 104 (TN); DTXSID0025527; HMS2233O07; HMS2235E05; HMS3259O14; HMS3884B10; CBP-1011; HY-B0469; KS-00001F8G; NSC21171; NSC26386; ZINC5029557; Tox21_111319; Tox21_200141; BDBM50067678; CM0089; s2567; AKOS015894870; Tox21_111319_1; AC-2174; CCG-264965; DB00603; NC00574; Medroxyprogesterone acetate (JP17/USP); MRF-0000023; NCGC00022037-03; NCGC00022037-04; NCGC00022037-05; NCGC00022037-07; NCGC00257695-01; NCGC00263480-01; AS-13981; SMR000653524; TV-46046; C08150; D00951; 16534-EP2269990A1; 16534-EP2272517A1; 16534-EP2275102A1; 16534-EP2275413A1; 16534-EP2281563A1; 16534-EP2281815A1; 16534-EP2287156A1; 16534-EP2289893A1; 16534-EP2289894A2; 16534-EP2295550A2; 16534-EP2298731A1; 16534-EP2298743A1; 16534-EP2298768A1; 16534-EP2301933A1; 16534-EP2305640A2; 16534-EP2308861A1; 16534-EP2311807A1; 16534-EP2311827A1; 16534-EP2314574A1; 16534-EP2316459A1; 92480-EP2295416A2; 92480-EP2295426A1; 92480-EP2295427A1; 92480-EP2298748A2; 92480-EP2298768A1; 92480-EP2305642A2; AB00384270-14; AB00384270_15; Medroxyprogesterone 17-acetate, >=97% (HPLC); 010M483; Q2823834; (6?)-6-Methyl-3,20-dioxopregn-4-en-17-yl acetate; 6.alpha.-Pregn-4-ene-3, 17-(acetyloxy)-6-methyl-; P097000000